Characterization of methamphetamine effects on the striatal-nigral dynorphin system.
Multiple high doses of methamphetamine (METH) induced 200-300% increases in the concentration of striatal and nigral dynorphin-like immunoreactivity (DLI). Increases in striatal and nigral DLI levels also were seen within 6 h following a single administration. The changes in the striatal-nigral dynorphin system had subsided 48 h after either acute or multiple treatments with METH. Selective lesioning of the nigral-striatal dopamine pathway blocked the effects; thus, the METH-induced changes appeared to be mediated by dopamine released from the nigral-striatal dopamine projection. Administration of the METH analog, 3,4-methylenedioxymethamphetamine, appeared to alter striatal and nigral DLI concentrations in a manner similar to that of METH.
Hanson
G R
GR
Department of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City 84112.
Merchant
K M
KM
Letter
A A
AA
Bush
L
L
Gibb
J W
JW
D015104:3,4-Methylenedioxyamphetamine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004399:Dynorphins / Q000502:physiology*; D006892:Hydroxydopamines / Q000494:pharmacology; D008297:Male; D008694:Methamphetamine / Q000378:metabolism / Q000494:pharmacology*; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D016627:Oxidopamine; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013378:Substantia Nigra / Q000187:drug effects / Q000378:metabolism*; D013563:Sympathectomy, Chemical
D006892:Hydroxydopamines; D008694:Methamphetamine; D015104:3,4-Methylenedioxyamphetamine; D004399:Dynorphins; D016627:Oxidopamine; D018817:N-Methyl-3,4-methylenedioxyamphetamine